Abstract
14C-rifabutin was given orally (25 mg/kg) and intravenously (i.v.) (10 mg/kg) to female Sprague-Dawley rats. Radioactivity was eliminated by both the renal and fecal routes, amounting to 44.49 and 43.39% of the dose, respectively, in urine and feces at 96 h after the oral dose and to 47.81 and 40.76% of the dose, respectively, in urine and feces after the i.v. dose. Differences between the two routes of administration were negligible. Tissue distribution of radioactivity after the oral dose was investigated by the combustion technique. At 2 h, the highest concentration of radioactivity was observed in the liver, followed by the lung, abdominal adipose tissue, and spleen, whereas at 72 h, the sequence was abdominal adipose tissue, liver, spleen, bone marrow, and lung. Brain levels of radioactivity were very low. The results of whole-body autoradiography after i.v. administration confirmed the above. Whole-body autoradiography of pregnant rats showed higher concentrations of radioactivity in the uterus than in the placenta and trace levels in the fetuses up to 8 h. Radioactivity was absent in the amniotic fluid. The urinary metabolism was studied by radio-high-pressure liquid chromatography. Rifabutin accounted for 7.4 and 7.2% of the dose in 0- to 48-h urine after oral and i.v. administration, respectively. Metabolites 31-OH rifabutin and 25-O-deacetyl rifabutin amounted to 4.3 and 1.6% of the dose, respectively, after oral administration and to 2.6 and 0.7% of the dose, respectively, after i.v. administration. The remaining urinary radioactivity was mainly due to polar compounds.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Akimoto T., Ono K., Nanpo T. [Absorption, distribution, metabolism and excretion of rifampicin (3-(4-methyl-1-piperazinyl-iminomethyl) rifamycin SV) in the rat]. Jpn J Antibiot. 1970 Jun;23(3):250–256. [PubMed] [Google Scholar]
- Battaglia R., Pianezzola E., Salgarollo G., Zini G., Strolin Benedetti M. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. J Antimicrob Chemother. 1990 Dec;26(6):813–822. doi: 10.1093/jac/26.6.813. [DOI] [PubMed] [Google Scholar]
- Biagi G. L., Barbaro A. M., Gamba M. F., Guerra M. C. Partition data of penicillins determined by means of reversed-phase thin-layer chromatography. J Chromatogr. 1969 May 20;41(3):371–379. doi: 10.1016/0021-9673(64)80150-3. [DOI] [PubMed] [Google Scholar]
- Binda G., Domenichini E., Gottardi A., Orlandi B., Ortelli E., Pacini B., Fowst G. Rifampicin, a general review. Arzneimittelforschung. 1971 Dec;21(12):1907–1977. [PubMed] [Google Scholar]
- Boman G. Tissue distribution of 14-C-rifampicin I. Whole body autoradiography of albino mice. Acta Pharmacol Toxicol (Copenh) 1975 Mar;36(3):257–266. doi: 10.1111/j.1600-0773.1975.tb00793.x. [DOI] [PubMed] [Google Scholar]
- Della Bruna C., Schioppacassi G., Ungheri D., Jabès D., Morvillo E., Sanfilippo A. LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies. J Antibiot (Tokyo) 1983 Nov;36(11):1502–1506. doi: 10.7164/antibiotics.36.1502. [DOI] [PubMed] [Google Scholar]
- ULLBERG S. Studies on the distribution and fate of S35-labelled benzylpenicillin in the body. Acta Radiol Suppl. 1954;118:1–110. [PubMed] [Google Scholar]
- Ungheri D., Della Bruna C., Sanfilippo A. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis. G Ital Chemioter. 1984 Sep-Dec;31(3):211–214. [PubMed] [Google Scholar]